What Researchers Did
Researchers conducted a randomized multicenter trial to evaluate the safety and feasibility of adding hyperbaric oxygen therapy to standard thrombolytic treatment for patients experiencing acute myocardial infarction.
What They Found
In an analysis of 112 patients, hyperbaric oxygen (HBO) combined with thrombolysis appeared feasible and safe. Patients receiving HBO showed an approximately 7.5% reduction in mean creatine phosphokinase (CPK) at 12 and 24 hours, shorter time to pain relief, and a discharge left ventricle ejection fraction (LVEF) of 51.7% compared to 48.4% in controls.
What This Means for Canadian Patients
For Canadian patients experiencing an acute myocardial infarction, these findings suggest that adjunctive hyperbaric oxygen therapy might offer benefits such as faster pain relief and potentially better heart function post-treatment. While more research is needed, this early evidence points to a possible complementary approach to standard thrombolytic care for improving recovery outcomes.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
A significant limitation is that the observed improvements in CPK reduction and left ventricle ejection fraction were not statistically significant, indicating the need for larger studies to confirm these potential benefits.